Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

PURPOSE: Approximately 40% of patients with advanced melanoma who received nivolumab combined with ipilimumab in clinical trials discontinued treatment because of adverse events (AEs). We conducted a retrospective analysis to assess the efficacy and safety of nivolumab plus ipilimumab in patients wh...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Schadendorf, Dirk, Wolchok, Jedd D., Hodi, F. Stephen, Chiarion-Sileni, Vanna, Gonzalez, Rene, Rutkowski, Piotr, Grob, Jean-Jacques, Cowey, C. Lance, Lao, Christopher D., Chesney, Jason, Robert, Caroline, Grossmann, Kenneth, McDermott, David, Walker, Dana, Bhore, Rafia, Larkin, James, Postow, Michael A.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2017
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5791828/
https://ncbi.nlm.nih.gov/pubmed/28841387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.2289
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky